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Abstract
Background: Sodium channel blockers augment ST-segment elevation in the right precordial leads in patients
undergoing Brugada-type electrocardiography (ECG). However, their effect on echocardiographic features is not
known. We address this by assessing global and regional ventricular function using conventional Doppler and two-
dimensional (2D) speckle tracking techniques.
Methods: Thirty-one patients with Brugada-type ECG were studied. A pure sodium channel blocker, pilsicainide,
was used to provoke an ECG response. The percentage longitudinal systolic myocardial strain at the base of both
the right ventricular (RV) free wall and the interventricular septum wall was measured using 2D speckle tracking.
Left ventricular (LV) and RV myocardial performance (TEI) indices were also measured.
Results: The pilsicainide challenge provoked a positive ECG response in 13 patients (inducible group). In the
inducible group, longitudinal strain was significantly reduced only at the RV (-27.3 ± 5.4% vs -22.1 ± 3.6%, P < 0.01),
and both RV and LV TEI indices increased (RV: 0.19 ± 0.09 vs 0.27 ± 0.11, P < 0.05; LV: 0.30 ± 0.10 vs 0.45 ± 0.10, P
< 0.01) after pilsicainide administration.
Conclusions: Temporal and spatial analysis using the TEI index and 2D strain imaging revealed the deterioration of
global ventricular function associated with conduction disturbance and RV regional function in patients with
Brugada-type ECG and coved type ST elevation due to administration of a sodium channel blocker.
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Background
Brugada syndrome is characterized by ST-segment eleva-
tion in right precordial leads and electrolyte disturbances
associated with a high risk of cardiac sudden death [1].
Despite these ST-segment changes in the ECG in this syn-
drome, no structural abnormalities have been detected by
conventional echocardiography. Drug challenge tests using
sodium channel blockers exaggerate ST segment elevation
when such elevation is initially absent, and have generally
become accepted as a useful method for diagnosing Bru-
gada syndrome [1-5]. A previous study demonstrated that
a sodium channel blocker, flecainide, induced a delay in
right ventricular (RV) activation in patients with Brugada
syndrome, using tissue Doppler imaging (TDI) [6]. Other
studies using electron-beam computed tomography scan
revealed that wall motion abnormalities in the RV outflow
wall were exacerbated by sodium channel blockers in
patients with Brugada syndrome [3,7]. These studies speci-
fically evaluated the timing and magnitude of RV contrac-
tion, however, the behavior of both global and regional RV
and left ventricular (LV) function in patients who showed
characteristic ECG changes after sodium channel blockade
is unknown.
Recently, two-dimensional (2D) strain imaging, based
on a speckle tracking technique, has been introduced to
evaluate regional myocardial function without angle
dependency [8]. Moreover, a myocardial performance
index (the TEI index) derived by temporal analysis of the
Doppler in- and outflow of the ventricle has been
accepted as a global ventricular functional index affected
by ventricular activation [9].
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tics in patients with Brugada-like ECG using 2D strain
imaging and the TEI index, and to clarify whether or
not changes in these indices occur according to the
ECG response to a sodium channel blocker.
Methods
Study group
We studied 31 patients with normal LV function evalu-
ated by 2D echocardiography with no evidence of typical
Brugada signs on their baseline ECG during hospitaliza-
tion. We enrolled the symptomatic patients who had a
history of documented arrhythmias other than ventricu-
lar tachycardia or ventricular fibrillation or episodes
related to syncope or fainting, but no documented
arrhythmias at that time, and the asymptomatic patients
with documented ECG abnormalities suspected of being
Brugada-type or like Brugada-type abnormalities. Their
ECG was either type 2, i.e. showing ST-segment elevation
(saddleback type) displaying J wave amplitude or ST-
segment elevation of ≥ 2 mm in more than one right pre-
cordial lead under baseline conditions, or type 3, i.e.
showing right precordial ST-segment elevation of
< 1 mm of the saddleback type, according to the Heart
Rhythm Society and the European Heart Rhythm Asso-
ciation [1].
Pilsicainide challenge
Pilsicainide was infused intravenously (1 mg/kg in 10 min-
utes) to provoke an ECG response. Drug administration
was immediately stopped when ST elevation (> 0.5 mV),
extensive QRS prolongation, unfavorable symptoms and
frequent ventricular arrhythmias were observed. No com-
plications resulted from these investigations. A positive
ECG response was defined as a > 200 mcV elevation of
t h eJw a v ea m p l i t u d ei nm o r et han one right precordial
lead [1,2] after pilsicainide infusion. Patients were subdi-
vided into two groups according to their ECG response to
pilsicainide:
Group 1: non-inducible (n = 18); pilsicainide chal-
lenge did not provoke ECG changes
Group 2: inducible (n = 13); pilsicainide challenge
provoked coved type ST elevation.
Patients with atrial fibrillation, a history of significant
coronary heart disease, valvular heart disease, cardio-
myopathy, a history of cardiac operation, or abnormal
LV systolic function were excluded from the study. The
protocol was approved by the Institutional Clinical
Research and Ethics Committee of the Yamaguchi Uni-
versity Hospital. Written informed consent was obtained
from all participants before the study.
Echocardiography and Doppler echocardiography
Echocardiography was performed with the patient in the
left lateral decubitus position at end-expiration using a
GE-Vingmed Vivid 7 system (GE-Vingmed Ultrasound
AS, Horten, Norway) equipped with a 2-4 MHz sector
transducer. Images were recorded at baseline conditions
and after pilsicainide. LV end-diastolic and end-systolic
dimensions were measured in the parasternal long-axis
view. The LV ejection fraction was obtained using the
biplane Simpson method from the apical four- and two-
chamber views. Both LV and RV inflow velocities were
obtained from the four- chamber view with the pulsed
wave Doppler sample volume positioned at the tips of the
mitral and tricuspid leaflets during diastole. The LV out-
flow velocity was obtained from the LV apical long-axis
view with the Doppler sample volume placed below the
aortic valve. The RV outflow velocity was obtained from
the parasternal short-axis view at the aortic valve level
with the Doppler sample volume placed below the pulmo-
nic valve. These velocity patterns were digitized and stored
in a hard disk on the ultrasound machine for 5 cardiac
cycles for further analysis. Both LV and RV TEI indexes,
as (a-b)/b,w h e r ea is the interval between cessation and
onset of transmitral (or transtricuspid) flow and b is the
aortic (or pulmonary) flow ejection time, were also mea-
sured by pulsed-Doppler echocardiography. The peak
velocities of early (E) and late (A) mitral inflow and the
deceleration time of the E wave (DcT) were measured
using pulse-wave Doppler. The isovolumic contraction
time (ICT) was measured as the time interval from the
cessation of LV inflow to the onset of LV outflow velocity.
2D strain imaging
LV apical four-chamber views were acquired using second
harmonic gray scale imaging. Three consecutive cardiac
cycles were acquired at end-expiratory apnea, and digitally
stored in a hard disk for offline analysis. The images were
processed on a workstation using EchoPAC Q (General
Electric, Waukesha, Wis) analysis software. The 2D strain
echocardiography used serial gray -scale sector images
based on frame-by- frame tracking of small rectangular
image blocks with stable speckle patterns [10]. The geo-
metric position of each marker changes from frame to
frame in accordance with the surrounding tissue motion.
The algorithm allows tracking of the new marker location
on each sequential image using correlation criteria and the
sum of absolute differences. The 2D strain imaging was
obtained by tracing the end-diastolic frame, and then the
software automatically tracked the contour on subsequent
frames. We obtained the percentage longitudinal myocar-
dial strain using 2D strain imaging at the base of both
the RV free wall and the interventricular septum (IVS)
(Figure 1).
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Values were expressed as means ± SD. Data were ana-
lyzed using analysis of variance to compare group differ-
ences followed by Scheffe’s multiple comparison test.
Group differences after pilsicainide were analyzed using
the 2-tailed Student’s t test. P values less than 0.05 were
considered significant.
A total of 15 studies were randomly selected for the
reanalysis of 2D strain data. The measurements were
repeated after 1week by same echocardiographer to
assess intraobserver reproducibility. Interobserver repro-
ducibility was assessed by a second observer who was
blind to the first observer’s measurements. Intraobserver
and interobserver reproducibility were analyzed using
both Pearson’s bivariate two-tailed correlations and
Bland-Altman analysis (with 95% agreement limits).
Results
The baseline characteristics are summarized in Table 1.
There were no differences in LV end-diastolic dimen-
sion, ejection fraction, and LA dimension between the
two groups. Table 2 lists the electrocardiographic and
echocardiographic variables in the baseline condition
and after pilsicainide infusion. There were no differences
in HR before and after pilsicainide in the non-inducible
and inducible groups. The PR and QRS intervals and
the QTc durations were significantly prolonged in both
the non-inducible and inducible groups after pilsicainide
infusion. The prolongation of the PR interval after pilsi-
cainide was greater in the inducible group than that in
Figure 1 Longitudinal myocardial strain using 2D strain imaging at the base of the right ventricular (RV) free wall (yellow) and the
interventricular septum (IVS) (red).
Table 1 Baseline characteristics of patients in the non-
inducible, inducible and baseline positive groups
Non-inducible Inducible p value
Age (yo) 46.9 ± 18.6 52.7 ± 16.5 NS
Male/Female 15/3 13/0 NS
LVDd (mm) 45.6 ± 3.8 46.5 ± 2.7 NS
LVEF (%) 68 ± 4.7 72.9 ± 4.6 NS
LAD (mm) 33 ± 4.4 33 ± 5.1 NS
Values are expressed as means ± SD. LVDd = left ventricular end-diastolic
dimension; LVEF = left ventricular ejection fraction; LAD = left atrial
dimension; NS = not significant
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transmitral inflow velocities (E/A) after pilsicainide were
higher in both groups compared with those in the base-
line condition, and the DcT was shortened in the non-
inducible group after pilsicainide. Neither the RV nor
the LV ejection time changed between before and after
pilsicainide infusion in the non-inducible and inducible
groups. Both RV and LV ICT in the inducible group
and LV ICT in the non-inducible group were prolonged
after pilsicainide infusion.
TEI index
Both RV- and LV-TEI indices at baseline were similar in
the 2 groups. After pilsicainide infusion, both RV- and
LV- TEI indices increased in the inducible groups. How-
ever, in the non-inducible group, the RV- and LV-TEI
indices did not change.
Longitudinal strain using 2D strain imaging
Longitudinal strain at the base of both RV and IVS in the
non-inducible group did not change throughout the study
as revealed by 2D strain imaging. However, longitudinal
s t r a i na tt h eb a s eo ft h eR Vi nt h ei n d u c i b l eg r o u p
decreased significantly after pilsicainide (-27.3 ± 5.4% vs
-22.1 ± 3.6%, P < 0.01) (Figures 2, 3). The reduction of RV
longitudinal strain after pilsicainide was greater in the
inducible group compared with that in the non-inducible
group (6.7 ± 2.8% vs -0.6 ± 3.7%, P < 0.01) (Figure 4).
There was no difference in the reduction of IVS longitudi-
nal strain between the non-inducible and inducible
groups.
Intraobserver and Interobserver Reproducibility
For intraobserver reproducibility, Pearson’s correlations
for longitudinal strain at the base of the RV free wall
and the IVS were r = 0.97 (P < 0.001) and r = 0.86 (P <
0.001), respectively. The limits of agreement for intraob-
server reproducibility were -6.0% to 5.0% in the RV free
wall and -3.3% to 2.8% in IVS. For interobserver repro-
ducibility, Pearson’s correlations at the base of the RV
free wall and the IVS were r = 0.86 (P < 0.001) and r =
0.81 (P < 0.001), respectively. The limits of agreement
for intraobserver reproducibility were -3.2% to 8.7% in
the RV free wall and -2.1% to 3.3% in the IVS.
Discussion
In this study, we observed the reduction of longitudinal
strain of basal segment of RV by 2D speckle tracking
techniques in patients with Brugada-type ECG and a
positive response to pilsicainide.
Brugada syndrome is characterized as ST-segment eleva-
tion from a depressed RV epicardial action potential dome
or a RV subepicardial action potential shortening [11,12].
Thus, Brugada syndrome has been described as “RV cardi-
omyopathy”. Some reports have revealed wall motion
abnormalities of the right ventricle in patients with Bru-
gada syndrome using cardiac CT [3,7] and MRI [13].
Modulation of wall motion by a sodium channel blocker
associated with ST-T elevation has also been found using
electron beam computed tomography [3]; however, no
echocardiographic studies demonstrated structural or
functional abnormalities in this syndrome.
RV longitudinal strain using 2D speckle tracking
Although previous studies reported a delay in the timing
of the onset of RV contraction using tissue Doppler
imaging in type 1 Brugada patients, regional RV or LV
function in such situations was not fully evaluated
[6,14]. In these previous studies, regional ventricular
function was evaluated using the tissue Doppler method;
however, impairment of RV tissue systolic velocity on
Table 2 Electrocardiographic and echocardiographic variables at baseline and after pilsicainide infusion
Non-inducible Inducible
Baseline Pilsicainide Baseline Pilsicainide
HR (bpm) 64.2 ± 8.2 66.9 ± 6.9 66.0 ± 14.1 67.7 ± 10.5
PR (ms) 157 ± 20.6 183 ± 44.4 ** 162 ± 14.9 211.6 ± 24.7 ** ✝
QRS (ms) 96.5 ± 12.7 121.2 ± 12.8 ** 106.4 ± 8.4 129.1 ± 11 **
QTc (ms) 399.2 ± 18.6 426 ± 21.5 ** 401.6 ± 17.2 429.9 ± 13.9 **
E/A 1.33 ± 0.53 1.71 ± 0.54 ** 1.56 ± 0.6 2.02 ± 0.91 **
DcT (ms) 205.0 ± 37.7 177.9 ± 29.9 ** 187.6 ± 28.4 172.6 ± 29.2
RV ET (ms) 315.3 ± 26.6 322.9 ± 28.6 326.8 ± 30.9 319.2 ± 28.0
LV ET (ms) 298.6 ± 20.7 301.5 ± 23.1 304.5 ± 28.6 289.4 ± 17.8
RV ICT (ms) 73.8 ± 16.5 76.1 ± 19.2 71.5 ± 6.6 89.35 ± 13.4 ** ✝
LV ICT (ms) 75.0 ± 21.2 84.9 ± 26.5 * 62.6 ± 5.8 72.9 ± 11.6 **
RV TEI index 0.19 ± 0.06 0.19 ± 0.05 0.19 ± 0.09 0.27 ± 0.11 * ✝
LV TEI index 0.31 ± 0.08 0.34 ± 0.08 0.30 ± 0.10 0.45 ± 0.10 ** ✝✝
Values are expressed as means ± SD. *P < .05 and **P < .01 vs corresponding value at baseline.
✝P < .05 and ✝✝P < .01 vs corresponding value in Non-inducible. HR, heart rate; E/A, ratio of early to late transmitral inflow velocity; DcT, deceleration time of
early transmitral inflow velocity; ET, ejection time; ICT, isovolumic contraction time
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measured longitudinal peak systolic strain as an index of
regional myocardial function using the 2D strain techni-
que and demonstrated depressed RV longitudinal strain.
This technique is a new method for quantifying regional
myocardial deformation based on high spatial resolution
speckle tracking without angle dependency [15-17], and
is not affected by translation or tethering from the sur-
rounding tissue [17-19]. Although the high variability
has been concerned for 2D strain analysis especially for
right ventricle, the evaluation of right as well as left ven-
tricular functions using this technique has been
accepted [20,21]. In the present study, we could also
confirm acceptable reproducibility for measuring
myocardial strain by this method. Previous studies have
found that electrical heterogeneity at the epicardium of
the RV is related to the genesis of Brugada syndrome
[11,12]. The augmentation of ST-segment elevation by
class IC anti-arrhythmic drugs has been reported
[2,4,22], and a possible mechanism for this augmenta-
tion in patients with Brugada syndrome has been pro-
posed [4,11]. The loss of the RV epicardial, but not
endocardial, action potential dome, which is facilitated
by strong sodium channel blockers creates a transmural
voltage gradient that manifests as an ST-segment eleva-
tion. This change of the action potential dome by pilsi-
cainide may cause attenuation of myocardial contractile
function and reduction of RV longitudinal strain.
Figure 2 Representative changes in longitudinal strain before and after pilsicainide infusion in the inducible and non-inducible
groups. Longitudinal strain at the base of the RV in the inducible group was significantly reduced after pilsicainide infusion (yellow arrow).
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Both the RV and LV TEI indices deteriorated in the
inducible group; however, these indices did not deterio-
rate in the non-inducible group. Although previous
study showed that the RV ejection time shortened as
the Brugada ECG pattern emerged after flecainide
infusion [6], we did not find a significant change in ejec-
tion time in either the non-inducible or inducible group.
Because pilsicainide has a less prolonged QRS duration
than flecainide [23], differences in electrophysiological
effects may contribute to the response of the ejection
time. In our study, despite no change in the ejection
Figure 3 Changes in longitudinal strain before and after pilsicainide infusion. Longitudinal strain at the base of both the RV and IVS in the
non-inducible group did not change; however, longitudinal strain at the base of the RV in the inducible group was significantly reduced after
pilsicainide infusion. PIL: pilsicainide
Figure 4 Reduction in longitudinal strain of the RV and the IVS after pilsicainide in the inducible and non-inducible groups.T h e
reduction in RV longitudinal strain after pilsicainide was greater in the inducible group compared with the non-inducible group.
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inducible group, was observed after pilsicainide. Because
the PR interval affected the ICT, the prolonged PR
caused prolongation of ICT and resulted in deterioration
of the TEI index. In addition to a negative inotropic
effect of pilsicainide, reduced RV function might affect
LV function through RV and LV interaction. This might
have caused the deterioration of the LV- TEI index in
the inducible group.
Study Limitations
A previous study reported that sodium channel blocker
administration resulted in ST-segment elevation and
RBBB in a patient with an SCN5A mutation [4]. We did
not perform genetic tests on the patients; therefore, the
relationship between pilsicainide challenge and genetic
tests is not known. Predicting the risk of cardiac events in
patients with Brugada-type ECG is important. In the pre-
sent study, since the number of study group was small and
the patients who showed positive response were limited,
we could not demonstrate the relation between RV strain
after pilsicainide infusion and incidence of fatal arrhyth-
mias. Although further investigation should be necessary,
this presented results may help risk stratification for
patients with Brugada-like ECG, and may facilitate to per-
form electrophysiologic study and to decide the indication
of implantable cardioverter defibrillator.
Conclusions
Although conventional echocardiography failed to detect
structural abnormalities in patients with Brugada-type
ECG and coved type ST elevation induced by a sodium
channel blocker, temporal and spatial analysis by TEI
index and 2D strain imaging revealed the deterioration of
global ventricular function associated with the manifesta-
tion of conduction disturbance and the reduction of RV
regional function.
List of abbreviations
RV: right ventricle/ventricular; LV: left ventricle/ventricular; 2D: two-
dimensional; TEI index: myocardial performance index; TDI: tissue Doppler
imaging; ICT: isovolumic contraction time.
Acknowledgements
The authors thank Drs. Eizo Akagawa and Yasuhiro Yoshiga for correction of
data.
Author details
1Division of Laboratory, Yamaguchi University Hospital, Ube, Japan.
2Department of Medicine and Clinical Science, Yamaguchi University
Graduate School of Medicine, Ube, Japan.
Authors’ contributions
KM conceived the study, participated in the study, performed
echocardiographic studies and drafted the manuscript. TU participated in
the study design of study. TT and YN participated in the study and
performed echocardiographic studies. YW performed echocardiographic and
statistical analyses. MM participated in echocardiographic studies and in the
study design. All authors have read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 9 August 2011 Accepted: 16 November 2011
Published: 16 November 2011
References
1. Wilde AA, Antzelevitch C, Borggrefe M, Brugada J, Brugada R, Brugada P,
Corrado D, Hauer RN, Kass RS, Nademanee K, et al: Proposed diagnostic
criteria for the Brugada syndrome. Eur Heart J 2002, 23(21):1648-1654.
2. Ueyama T, Shimizu A, Yamagata T, Esato M, Ohmura M, Yoshiga Y,
Kanemoto M, Kametani R, Sawa A, Suzuki S, et al: Different effect of the
pure Na+ channel-blocker pilsicainide on the ST-segment response in
the right precordial leads in patients with normal left ventricular
function. Circ J 2007, 71(1):57-62.
3. Takagi M, Aihara N, Kuribayashi S, Taguchi A, Kurita T, Suyama K,
Kamakura S, Takamiya M: Abnormal response to sodium channel blockers
in patients with Brugada syndrome: augmented localised wall motion
abnormalities in the right ventricular outflow tract region detected by
electron beam computed tomography. Heart 2003, 89(2):169-174.
4. Brugada R, Brugada J, Antzelevitch C, Kirsch GE, Potenza D, Towbin JA,
Brugada P: Sodium channel blockers identify risk for sudden death in
patients with ST-segment elevation and right bundle branch block but
structurally normal hearts. Circulation 2000, 101(5):510-515.
5. Antzelevitch C, Brugada P, Borggrefe M, Brugada J, Brugada R, Corrado D,
Gussak I, LeMarec H, Nademanee K, Perez Riera AR, et al: Brugada
syndrome: report of the second consensus conference: endorsed by the
Heart Rhythm Society and the European Heart Rhythm Association.
Circulation 2005, 111(5):659-670.
6. Tukkie R, Sogaard P, Vleugels J, de Groot IK, Wilde AA, Tan HL: Delay in
right ventricular activation contributes to Brugada syndrome. Circulation
2004, 109(10):1272-1277.
7. Takagi M, Aihara N, Kuribayashi S, Taguchi A, Shimizu W, Kurita T, Suyama K,
Kamakura S, Hamada S, Takamiya M: Localized right ventricular
morphological abnormalities detected by electron-beam computed
tomography represent arrhythmogenic substrates in patients with the
Brugada syndrome. Eur Heart J 2001, 22(12):1032-1041.
8. Marwick TH: Measurement of strain and strain rate by echocardiography:
ready for prime time? J Am Coll Cardiol 2006, 47(7):1313-1327.
9. Duncan AM, Francis DP, Henein MY, Gibson DG: Importance of left
ventricular activation in determining myocardial performance (Tei)
index: comparison with total isovolumic time. Int J Cardiol 2004, 95(2-
3):211-217.
10. Reisner SA, Lysyansky P, Agmon Y, Mutlak D, Lessick J, Friedman Z: Global
longitudinal strain: a novel index of left ventricular systolic function. J
Am Soc Echocardiogr 2004, 17(6):630-633.
11. Gussak I, Antzelevitch C, Bjerregaard P, Towbin JA, Chaitman BR: The
Brugada syndrome: clinical, electrophysiologic and genetic aspects. JA m
Coll Cardiol 1999, 33(1):5-15.
12. Yan GX, Antzelevitch C: Cellular basis for the Brugada syndrome and
other mechanisms of arrhythmogenesis associated with ST-segment
elevation. Circulation 1999, 100(15):1660-1666.
13. Sato Y, Kato K, Hashimoto M, Akiyama H, Matsumoto N, Takase H, Ogawa K,
Sakamaki T, Yagi H, Kanmatsuse K: Localized right ventricular structural
abnormalities in patients with idiopathic ventricular fibrillation: magnetic
resonance imaging study. Heart Vessels 1996, 11(2):100-103.
14. Babaee Bigi MA, Moaref AR, Aslani A: Interventricular mechanical
dyssynchrony: a novel marker of cardiac events in Brugada syndrome.
Heart Rhythm 2008, 5(1):79-82.
15. Korinek J, Wang J, Sengupta PP, Miyazaki C, Kjaergaard J, McMahon E,
Abraham TP, Belohlavek M: Two-dimensional strain - a Doppler-
independent ultrasound method for quantitation of regional
deformation: validation in vitro and in vivo. J Am Soc Echocardiogr 2005,
18(12):1247-1253.
16. Korinek J, Kjaergaard J, Sengupta PP, Yoshifuku S, McMahon EM, Cha SS,
Khandheria BK, Belohlavek M: High spatial resolution speckle tracking
improves accuracy of 2-dimensional strain measurements: an update on
Murata et al. Cardiovascular Ultrasound 2011, 9:30
http://www.cardiovascularultrasound.com/content/9/1/30
Page 7 of 8a new method in functional echocardiography. J Am Soc Echocardiogr
2007, 20(2):165-170.
17. Amundsen BH, Helle-Valle T, Edvardsen T, Torp H, Crosby J, Lyseggen E,
Stoylen A, Ihlen H, Lima JA, Smiseth OA, et al: Noninvasive myocardial
strain measurement by speckle tracking echocardiography: validation
against sonomicrometry and tagged magnetic resonance imaging. JA m
Coll Cardiol 2006, 47(4):789-793.
18. Edvardsen T, Gerber BL, Garot J, Bluemke DA, Lima JA, Smiseth OA:
Quantitative assessment of intrinsic regional myocardial deformation by
Doppler strain rate echocardiography in humans: validation against
three-dimensional tagged magnetic resonance imaging. Circulation 2002,
106(1):50-56.
19. Leitman M, Lysyansky P, Sidenko S, Shir V, Peleg E, Binenbaum M, Kaluski E,
Krakover R, Vered Z: Two-dimensional strain-a novel software for real-
time quantitative echocardiographic assessment of myocardial function.
J Am Soc Echocardiogr 2004, 17(10):1021-1029.
20. Meris A, Faletra F, Conca C, Klersy C, Regoli F, Klimusina J, Penco M,
Pasotti E, Pedrazzini GB, Moccetti T, et al: Timing and magnitude of
regional right ventricular function: a speckle tracking-derived strain
study of normal subjects and patients with right ventricular dysfunction.
J Am Soc Echocardiogr 2010, 23(8):823-831.
21. Pedrinelli R, Canale ML, Giannini C, Talini E, Dell’Omo G, Di Bello V:
Abnormal right ventricular mechanics in early systemic hypertension: a
two-dimensional strain imaging study. Eur J Echocardiogr 2010,
11(9):738-742.
22. Nagase S, Kusano KF, Morita H, Fujimoto Y, Kakishita M, Nakamura K,
Emori T, Matsubara H, Ohe T: Epicardial electrogram of the right
ventricular outflow tract in patients with the Brugada syndrome: using
the epicardial lead. J Am Coll Cardiol 2002, 39(12):1992-1995.
23. Kanemoto M, Shimizu A, Yamagata T, Esato M, Ueyama T, Yoshiga Y,
Kakugawa H, Kametani R, Inoue N, Sawa A, et al: Differentiation of the
electrophysiological effects on the atrial myocardium between the pure
Na channel blocker, pilsicainide, and flecainide. Cardiovasc Drugs Ther
2004, 18(4):295-303.
doi:10.1186/1476-7120-9-30
Cite this article as: Murata et al.: Right ventricular dysfunction in
patients with Brugada-like electrocardiography: a two dimensional
strain imaging study. Cardiovascular Ultrasound 2011 9:30.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Murata et al. Cardiovascular Ultrasound 2011, 9:30
http://www.cardiovascularultrasound.com/content/9/1/30
Page 8 of 8